Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00172172 | Calcium Supplementation in Postmenopausal Women | PHASE3 | COMPLETED | 374 | — | — | Jan 10, 2004 | Mar 11, 2005 | May 25, 2021 | 27 | United States, Argentina +1 |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | PTH 100 mcg and 700 mg calcium |
| 2 | EXPERIMENTAL | PTH 100 mcg and placebo |
| 3 | PLACEBO_COMPARATOR | Placebo and 700 mg calcium |
| Name | Type | Description |
|---|---|---|
| PTH/Calcium | DRUG | PTH(1-84) subcutaneous injection and calcium 700 mg oral |
| PTH/placebo | DRUG | PTH (1-84) injected subcutaneously and placebo provided orally |
| placebo | DRUG | Placebo injected subcutaneously and 700 mg calcium orally |
Inclusion Criteria: * Women who are capable of understanding and giving written, voluntary informed consent before the clinical study screening visit * Women with the ability to self-administer a daily injection or having a designee who will give the injections * Women who are postmenopausal with a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | NA | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | — | Undisclosed |